- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterSunday, May 19, 2002
 |
 Maggie Hampshire, RN, BSN, OCN, Managing Editor, and Janet E. Finnegan, RN discuss OncoLink. |
|
A Phase II Trial of Celecoxib (CX), Irinotecan (I), 5-Fluorouracil (5FU), and Leucovorin (LCV) in Patients with Unresectable or Metastatic Colorectal Cancer (CRC)
Presenter: C.D. BlankePresenter's Affiliation: Oregeon Health Sciences UniversityType of Session: ScientificBackground Previous studies have shown that cyclooxygenase-II (COX-2) is present in the majority of CRCs, with expression associated with... |
|
|
A randomized phase III trial of preoperative chemoradiation followed by surgery (CR-S) versus surgery alone (S) for localized resectable cancer of the esophagus
Presenter: B. H. BurmeisterPresenter's Affiliation: Trans Tasmanian Radiation Oncology Group, Australasian Gastrointestinal Trials Group, and Clinical Trials Centre, Sydney, AustraliaType of Session: ScientificBackground Previous randomized studies... |
|
|
Cetuximab (C225) Plus Irinotecan (CPT-11) Plus Infusional 5FU/Folinic Acid (FA) is Safe and Active in Metastatic Colorectal Cancer (MCRC) that Expresses Epidermal Growth Factor Receptor (EGFR)
Presenter: P. SchoffskiPresenter's Affiliation: Hannover Medical School (Hannover, Germany)Type of Session: PosterBackground EGFR is a transmembrane glycoprotein receptor overexpressed in many human solid tumors. EGFR is a mediator of intracellular... |
|
|
Cetuximab (IMC-C225) plus Weekly Irinotecan (CPT-11), Fluorouracil (5FU), and Leucovorin (LV) in Colorectal Cancer (CRC) that Expresses the Epidermal Growth Factor Receptor (EGFR)
Presenter: Arthur RosenbergPresenter's Affiliation: The Bendheim Cancer Center of Greenwich Hospital, ConnecticutType of Session: PosterBackground Previous studies have shown that increased expression of Epidermal Growth Factor Receptor (EGFR)... |
|
|
Efficacy and Tolerability of Two Dosing Regimens of R115777 (Zarnestra), a Farnesyl Protein Transferase Inhibitor, in Patients with Advanced Breast Cancer
Presenter: Stephen R. JohnstonPresenter's Affiliation: Royal Bournemouth Hospital, Bournemouth, UKType of Session: ScientificBackground Farnesylation is a process that activates proteins involved in growth factor dependent signal transduction... |
|
|
Final Results From A Phase II Trial Of Zd1839 ('Iressa') For Patients With Advanced Non-Small-Cell Lung Cancer (IDEAL 1)
Presenter: Masahiro FukuokaPresenter's Affiliation: Kinki University, Osaka, JapanType of Session: PosterBackground Iressa is an oral preparation of a selective inhibitor of the epidermal growth factor receptor tyrosine kinase It interferes with... |
|
|
Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG)
Presenter: C. SederholmPresenter's Affiliation: University Hospital, Linkoping, SwedenType of Session: ScientificBackground Chemotherapy is indicated in patients with locally advanced and metastatic lung cancer who have good performance status and... |
|
|
Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non-small cell lung cancer (NSCLC): final results of Czech Lung Cancer Cooperative Group phase III randomized trial
Presenter: L. NovakovaPresenter's Affiliation: Czech Lung Cancer Cooperative GroupType of Session: PosterBackground Advanced non-small cell lung cancer has a poor survival. A majority of the patients fail distantly, with metastatic disease. ... |
|
|
Incorporating Angiogenesis Inhibition with Bevacizumab (anti-VEGF) into Frontline Chemotherapy with Irinotecan (CPT-11), Fluorouracil and Leucovorin (FU/LV) for Advanced Colorectal Cancer (advCRC): A Toxicity Analysis of ECOG Study E2200
Presenter: B.J. GiantonioPresenter's Affiliation: University of PennsylvaniaType of Session: ScientificBackground Anti-angiogenesis therapy has received much publicity recently. Such molecularly-targeted therapies hold promise as the next wave of... |
|
|
Inhibition of Epidermal Growth Factor/HER2 Receptor Signaling Using ZD1839
Presenter: S. MassarwehPresenter's Affiliation: Baylor Breast CenterType of Session: ScientificBackground Resistance of some breast cancers to endocrine therapy remains a problem for clinicians. Research into preventing or reversing endocrine... |
|
|
Long Term Survival Of Stage II And III Melanoma Patients With Respect To Serial Tyrosinase RT-PCR Testing In Peripheral Blood
Presenter: Christiane A VoitPresenter's Affiliation: University of Mainz, Mainz, GermanyType of Session: ScientificBackground Melanoma has a high metastatic potential even in small primary lesions, and an early distinction between localized and... |
|
|
Lymphatic Mapping And Sentinel Lymph Node Sampling In Breast Cancer: A Meta-Analysis
Presenter: T. KimPresenter's Affiliation: Albany Medical CenterType of Session: ScientificBackground Sentinel lymph node sampling (SLNS) in breast cancer has become a common practice There is a lack of randomized clinical trials comparing SLNS to... |
|
|
Multicenter Phase II Trial Of Paclitaxel (P), Ifosfamide (I), And Carboplatin (C) In Previously Untreated Extensive Stage Small Cell Lung Cancer (ES?SCLC)
Presenter: Marcus A NeubauerPresenter's Affiliation: US Oncology Inc, Houston, TXType of Session: PosterBackground ES-SCLC accounts for 60-70% of the 30-35,000 new cases of SCLC diagnosed each year in the US The median survival for ES-SCLC reported... |
|
|
Phase III Trail Comparing TAC (docetaxel, dosorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 Study
Presenter: J-M NabholtzPresenter's Affiliation: Breast Cancer International Research Group (BCIRG)Type of Session: ScientificBackground Doxorubin and cyclophosphamide, with or without 5-fluorouracil, are standard chemotherapy agents in the adjuvant... |
|
|
Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC)
Presenter: H. ChoyPresenter's Affiliation: ACRType of Session: ScientificBackground The majority of NSCLC patients present with inoperable disease. Therefore, the definitive treatment is with a combination of chemotherapy (most notably platinum... |
|
|
Sequential Adjuvant Chemo-Radiotherapy With Vs. Without Erythropoeitin For Patients With High-Risk Cervical Cancer-Second Analysis Of A Prospective, Randomized, Open And Controlled AGO- AND Sequential Adjuvant Chemo-Radiotherapy With Vs. Without Erythropoeitin For Patients With High-Risk Cervical Cancer-Second Analysis Of A Prospective, Randomized, Open And Controlled AGO- And NOGGO-Intergroup Study
Presenter: Jens U BlohmerPresenter's Affiliation: Humboldt University, Berlin, GermanyType of Session: PosterBackground The aim of the study was to compare the disease-free survival achieved by an adjuvant sequential chemoradiotherapy regimen with... |
|
|
Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
Presenter: L. SaltzPresenter's Affiliation: Memorial Sloan-Kettering Cancer CenterType of Session: ScientificBackground In a previous trial (reported at ASCO last year), IMC-C225, in combination with CPT-11, was demonstrated to have a 22.5% response... |
|
|
The Role Of Sentinel Lymphadenectomy In Thin Cutaneous Melanomas
Presenter: Richard J. BleicherPresenter's Affiliation: The John Wayne Cancer Institute, Santa Monica, CAType of Session: ScientificBackground The sentinel lymph node (SLN) biopsy is revolutionizing the surgical management of primary malignant... |
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
